Mechanisms of response to anti-angiogenesis therapy in CTNNB1-mutated endometrial cancers

被引：2
|
作者：
Berger, A. A. [1 ]
Jelinic, P. [2 ]
Levine, D. A. [1 ,2 ]
机构：
[1] NYU, Sch Med, New York, NY USA
[2] NYU Langone Hlth, New York, NY USA
来源：
GYNECOLOGIC ONCOLOGY | 2019年 / 154卷
关键词：
D O I：
10.1016/j.ygyno.2019.04.120
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1119
引用
收藏
页码：50 / 50
页数：1
相关论文
共 50 条
  • [1] Large-scale proteomic analysis of mechanisms of response to anti-angiogenesis therapy in CTNNB1-mutated endometrial cancers
    Kawaler, E. A.
    Berger, A. A.
    Ruggles, K. V.
    Levine, D. A.
    GYNECOLOGIC ONCOLOGY, 2019, 154 : 76 - 76
  • [2] CLINICOPATHOLOGICAL CHARACTERISTICS OF WOMEN WITH CTNNB1-MUTATED ENDOMETRIAL CANCER
    Knez, J.
    Sobocan, M.
    Kavalar, R.
    Zupin, M.
    Buedefeld, T.
    Potocnik, U.
    Takac, I.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A101 - A101
  • [3] Inhibiting Wnt/beta-catenin in CTNNB1-mutated endometrial cancer
    Moroney, Marisa R.
    Woodruff, Elizabeth
    Qamar, Lubna
    Bradford, Andrew P.
    Wolsky, Rebecca
    Bitler, Benjamin G.
    Corr, Bradley R.
    MOLECULAR CARCINOGENESIS, 2021, 60 (08) : 511 - 523
  • [4] Angiogenesis in gynecological cancers and the options for anti-angiogenesis therapy
    Yetkin-Arik, Bahar
    Kastelein, Arnoud W.
    Klaassen, Ingeborg
    Jansen, Charlotte H. J. R.
    Latul, Yani P.
    Vittori, Milos
    Biri, Aydan
    Kahraman, Korhan
    Griffioen, Arjan W.
    Amant, Frederic
    Lok, Christianne A. R.
    Schlingemann, Reinier O.
    van Noorden, Cornelis J. F.
    BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2021, 1875 (01):
  • [5] LKB1 signaling is activated in CTNNB1-mutated HCC and positively regulates β-catenin-dependent CTNNB1-mutated HCC
    Charawi, Sara
    Just, Pierre-Alexandre
    Savall, Mathilde
    Abitbol, Shirley
    Traore, Massire
    Metzger, Nolwenn
    Ravinger, Roland
    Cavard, Catherine
    Terris, Benoit
    Perret, Christine
    JOURNAL OF PATHOLOGY, 2019, 247 (04): : 435 - 443
  • [6] Targeting beta-catenin and Wnt signaling in CTNNB1-mutated endometrial cancer.
    Moroney, Marisa R.
    Woodruff, Elizabeth R.
    Qamar, Lubna
    Bitler, Benjamin G.
    Corr, Bradley R.
    CLINICAL CANCER RESEARCH, 2021, 27 (03)
  • [7] The role of CTNNB1 mutations and matrix metalloproteinases (MMPs) in anti-angiogenesis treatment of endometrial carcinoma
    Berger, Amnon A.
    Kawaler, Emily A.
    Dao, Fanny
    Misirlioglu, Selim
    Fernandez, Ernesto Arostegui
    Olvera, Narciso
    Van Oudenhove, Elke
    DeLair, Deborah
    Levine, Douglas A.
    GYNECOLOGIC ONCOLOGY, 2022, 167 (02) : 323 - 333
  • [8] Identification of Mutated β-catenin Gene Signature (MBGS) to Identify CTNNB1-mutated and Immune Checkpoint Resistant Hepatocellular Cancers
    Lehrich, Brandon M.
    Tao, Junyan
    Cao, Catherine
    Yasaka, Tyler M.
    Delgado, Evan R.
    Hirsch, Theo
    Liu, Yuqing
    Singh, Sucha
    Poddar, Minakshi
    Pan, Long
    Liu, Silvia
    Singhi, Aatur
    Zucman-Rossi, Jessica
    Monga, Satdarshan P.
    AMERICAN JOURNAL OF PATHOLOGY, 2024, 194 (04): : S18 - S19
  • [9] LEF1 Immunohistochemistry Identifies CTNNB1-mutated Medulloblastomas
    Thomas, Diana
    Murdoch, Geoffrey
    Hamilton, Ronald
    JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY, 2017, 76 (06): : 541 - 542
  • [10] Expanding the phenotype of CTNNB1-mutated individuals and description of the fetal phenotype
    Wells, C. F.
    Heide, S.
    Charles, P.
    Marey, I.
    Heron, D.
    Nava, C.
    Courtin, T.
    Isidor, B.
    Piton, A.
    Gerard, B.
    Buratti, J.
    Fradin, M.
    Dubourg, C.
    Pasquier, L.
    Faivre, L.
    Philip, N.
    Milh, M.
    Lesca, G.
    Edery, P.
    Sanlaville, D.
    Liquier, A.
    Dieux, A.
    Attie-Bitach, T.
    Colin, E.
    Bonneau, D.
    Keren, B.
    Genevieve, D.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2019, 27 : 216 - 217
12345